Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) shares are trading higher by 10.5% at $151.00 after the company reported better-than-expected fourth-quarter EPS and sales results.
Jazz Pharmaceuticals reported quarterly earnings of $4.21 per share which beat the analyst consensus estimate of $3.63. Jazz Pharmaceuticals also reported quarterly sales of $896.73 million which beat the analyst consensus estimate of $865.88 million by 4%. This is a 35% increase over sales of $665.52 million the same period last year.
Jazz Pharmaceuticals highlighted the following business notes from the fourth-quarter:
- Positive early feedback underpins November 2021 launch of Xywav® for idiopathic hypersomnia
- Drove exceptional Xywav adoption in narcolepsy in 2021
- Epidiolex/Epidyolex® year-over-year revenue growth of 29% underscores blockbuster potential
- Rapidly established Zepzelca as the treatment of choice in second-line SCLC
- Rylaze launch progressing well with strong early demand
- Significant revenue diversification with 59% of net product sales in 4Q21 from products launched or acquired since 2019
- Advanced value-driving pipeline programs with 5 key trials initiated in 2H21
- Entering 2022 well-positioned to deliver on Vision 2025
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology.
Jazz Pharmaceuticals has a 52-week high of $189.00 and a 52-week low of $117.64.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga